

---

## **HARPREET S. BAJAJ, MD, MPH, ECNU, FACE**

*Epidemiologist & Endocrinologist, LMC Diabetes & Endocrinology  
Director of Late-Phase Research, LMC Healthcare  
Research Associate, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto  
Vice Chair, Clinical Practice Guidelines, Diabetes Canada  
Co-Chair, Marketing and Communication, Professional Section National Executive, Diabetes Canada  
National Consultant Editor, Canadian Journal of Diabetes  
Columnist, Medscape  
Founding Chairman, "STOP Diabetes" Foundation Inc.*

Office address: 2979 Bovaird Drive East, Brampton, ON L6S 0C6, Canada  
Email: [harpreet.bajaj@lmc.ca](mailto:harpreet.bajaj@lmc.ca) ~ Tel: (905) 595-0560 ~ Fax: (905) 595-0562

---

### **INTRODUCTION**

A meticulous and compassionate physician for my patients; an enthusiastic and motivational speaker for the public; a focused researcher and a friend for my colleagues; a knowledgeable and likable teacher for my students. I have learnt from each of my eclectic experiences and have evolved into a clinician who can adapt to varied professional situations and can readily apply evidence-based medicine to the benefit of patient care and population prevention efforts alike.

---

### **EDUCATION AND TRAINING**

|   |                        |
|---|------------------------|
| Maulana Azad Medical College, University of Delhi, India<br>Bachelor of Medicine and Bachelor of Surgery<br>Degree awarded: June 2001 | Aug. 1995 to Dec. 1999 |
| University at Albany SUNY, NY, USA<br>Master of Public Health (MPH), Concentration: Epidemiology<br>Degree awarded: May 2006          | Sept. 2002 to May 2004 |
| Hennepin County Medical Center, Minneapolis, MN, USA<br>Clinical Internship and Residency in Internal Medicine                        | June 2004 to June 2007 |
| Cleveland Clinic, Cleveland, OH, USA<br>Clinical Fellowship in Endocrinology, Diabetes and Metabolism                                 | July 2007 to June 2009 |

---

### **CURRENT APPOINTMENTS**

|   |                      |
|---|----------------------|
| LMC Healthcare, Toronto<br>Director of Late-Phase (Phase II-IV) Research                  | Jan. 2019 to present |
| Diabetes Canada<br>Vice Chair, Clinical Practice Guidelines                               | Jan. 2019 to present |
| Mount Sinai Hospital, Toronto<br>Research Associate, Leadership Sinai Centre for Diabetes | Mar. 2016 to present |
| LMC Diabetes & Endocrinology, Brampton<br>Epidemiologist & Endocrinologist                | July 2009 to present |

---

### **ADDITIONAL APPOINTMENTS AND MEMBERSHIPS**

- Chair, Canadian expert forum for Diabetes and Ramadan, with the assigned task of developing a Canadian Ramadan position statement in collaboration with Diabetes Canada; *January 2018-May 2018*
- Chapter author and Expert committee member, *Diabetes Canada Clinical Practice Guidelines 2018*
- Columnist and Endocrinology ad-board member; *Medscape* and *WebMD*; September 2017 – ongoing
- Co-Chair, Marketing and Communication, Professional Section National Executive, *Diabetes Canada (formerly Canadian Diabetes Association -CDA)*; Oct 2016 - ongoing
- National Consultant Editor, *Canadian Journal of Diabetes (CJD)*; Oct 2015 - ongoing
- Councilor, *Diabetes Canada (formerly CDA) Clinical & Scientific Section Executive*; Oct 2014 – Oct 2016
- Founding Chairman, “*STOP Diabetes*” *Foundation Inc.*; 2014-ongoing
- Member of CME planning committee for *iENDO* in Toronto; 2012-2017
- Chairman of Tariff committee of *Ontario Medical Association (OMA) Endocrine section*; 2011-2017
- Member of planning committee for city-wide *LMC endocrinology rounds*; 2011-ongoing
- Co-chair of CME committee, *North Indian Medical & Dental Association of Canada (NIMDAC)*; 2014-2016
- Chief fellow at Endocrinology fellowship program; Cleveland Clinic, OH; 2008-09
- Fellow representative of Internal Medicine internal review committee; Cleveland Clinic, OH; 2009
- Leader of epidemiology & statistics monthly endocrine journal club at Cleveland Clinic, OH; 2007-2009
- Leader of monthly Internal Medicine resident journal club at Hennepin County Medical Center in Minneapolis, MN; 2005-2007
- Active member of Diabetes Canada, Canadian Society of Endocrine and Metabolism (CSEM), American Diabetes Association (ADA), European Association for Study of Diabetes (EASD), Ontario Medical Association (OMA), American Association of Clinical Endocrinologists (AACE)
- Graduate administrative assistant at School of Public Health, University at Albany, NY; 2002-2003
- Junior Residency (Externship) in Emergency Department, Government of Delhi Hospitals, New Delhi, India, Apr. 2001 to Jul. 2002
- Clinical Internship; Maulana Azad Medical College, New Delhi, India; Jan. 2000 to Jan. 2001
- Member of events organizing committee; Maulana Azad Medical College, New Delhi, India; 1997-1998

---

### TEACHING

- Adjunct Lecturer, Endocrinology fellowship program, McMaster University in Hamilton; 2013- ongoing
- Faculty and planning committee member , Endocrine neck ultrasound workshop at the *Canadian Society for Endocrinology and Metabolism/ Diabetes Canada Annual Professional* ; 2016-2017
- Guest Lecturer, Endocrinology fellowship program, University of Toronto; 2015
- Guest Lecturer, Endocrinology fellowship program, University of Western Ontario in London; 2014
- Staff leader of Endocrinology classroom program, teaching second-year medical students at Cleveland Clinic Lerner College of Medicine; 2007-2009
- Teaching assistant in Statistical Analysis Software (SAS) course at University of Albany School of Public Health; 2002-2003

---

### CERTIFICATIONS, FELLOWSHIPS AND LICENCES

|      |  |
|------|--|
| 2013 | Fellow of American College of Endocrinology (FACE)   |
| 2011 | Endocrine Certification in Neck Ultrasound (ECNU) from American College of Endocrinology (ACE)     |
| 2009 | American Board of Internal Medicine certification (ABIM) in Endocrinology, Diabetes and Metabolism |
| 2009 | College of Physicians and Surgeons of Ontario (CPSO) certification                                 |
| 2009 | Certification in Clinical Densitometry from International Society for Clinical Densitometry (ISCD) |
| 2007 | CITI certification course in Protection of Human Research Subjects                                 |
| 2007 | American Board of Internal Medicine (ABIM) certification in Internal Medicine                      |
| 2007 | Ohio Medical Licensure   |
| 2004 | BCLS/ACLS certification  |
| 2004 | Minnesota Training Certification   |
| 2003 | Education Commission for Foreign Medical Graduates (ECFMG) certification                           |

### VOLUNTEER PUBLIC HEALTH EDUCATION & ADVOCACY

- 
- Keynote speaker, 11th Annual South Asian Expo organized by Diabetes Canada in Brampton, Ontario on 24 November 2018
  - Steering committee member, Healthy Communities Initiative of the Central West Local Health Integration Network (CW LHIN), City of Brampton, Region of Peel and William Osler Health System; 2016-ongoing

- TV show host for weekly “Your Health” health education program on Canadian South Asian Channel Y; January 2016-ongoing
- Monthly health show on Parvasi radio (CJMR 1320); March 2016-December 2017
- Founder and Director of registered charitable organization “STOP Diabetes” Foundation Inc. which has a mission of helping public awareness on diabetes, especially focusing on South Asian community; 2014-ongoing
- Health expert: media (newspapers, radio and TV) appearances for public health education on prevention of diabetes; 2012-ongoing
- Leader of public awareness seminars on prevention and management of diabetes at health fairs in Brampton; volunteer with *Bramalea Community Health Center*; 2009-ongoing
- Leader of a public diabetes seminar at Gurudwara Dukh Nivaran in Surrey, BC; October 2017
- Guest speaker at public awareness seminar “Does sugar cause diabetes” organized by Dil walk Foundation, Calgary; February 2017
- Guest speaker at public awareness seminar on diabetes prevention organized by Apni Sehat Apni Parvah (ASAP), Montreal; December 2015
- Guest speaker at public awareness seminars on prevention and management of diabetes at workshops organized by *South Asian diabetes chapter of Canadian Diabetes Association*; 2013-14
- Leader of public education seminars on prevention of diabetes and obesity at events organized by *Peel Women Health and Social Service*; 2011
- Endocrinologist responsible for thyroid ultrasounds at *Women’s Health Fair* in Cleveland Clinic, August 2008
- Endocrinologist volunteer at *Camp Ho Mita Koda* for children with Type 1 Diabetes; June 2008
- Diabetes consultation education at Health Fair, Shiva Vishnu temple, Cleveland; 2007 and 2008
- Diabetes consultation education at Health Fair at Guru Gobind Singh Gurudwara of Greater Cleveland; 2008
- Organized *Red Cross* blood donation camp at School of Public Health, SUNY, NY; February 2004
- Participated in the Family Health Advisory Program as a medical student in New Delhi, India; 1995-1999

---

#### AWARDS & COMPETITIONS

---

- November 2018            LMC Healthcare annual general meeting  
*Excellence in Patient Care* award
- November 2016            LMC Diabetes & Endocrinology annual general meeting  
*Excellence in Research* award
- November 2013            LMC Diabetes & Endocrinology annual general meeting  
*Physician Rockstar* award for clinical and research work
- June 2009                    Cleveland Clinic graduation day  
*William E. Lower clinical research award* for academic year 2008-2009
- September 2008            AACE and Cleveland Clinic’s 11<sup>th</sup> annual Endocrinology & Metabolism Board Review  
Winner of *Who wants to be an endocrine millionaire?* contest among U.S. Endocrinology fellows
- May 2008                    American Association of Clinical Endocrinologists (AACE) 17<sup>th</sup> annual meeting  
Winner of *Medical Jeopardy* contest among U.S. Endocrinology fellows
- June 2004-2007            Hennepin County Medical Center graduation day  
Winner of *EKG of the week* contest among Internal Medicine residents for three consecutive years 2004-2007.
- June 2006                    Hennepin County Medical Center graduation day  
Winner of *Ethics question of the week* contest among Internal Medicine residents for academic year 2005-2006
- April 2006                    University of Albany School of Public Health student poster day  
*Health Research Inc. / David Axelrod Award for Excellence in Research*

---

#### PEER-REVIEWED PUBLICATIONS (PUBMED INDEXED)

---

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD; Rose JB, Sorabji D, [Bajaj HS](#); *CANadian CANagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice*. *Can J Diabetes*. Accepted for publication 2019

Dailey G, [Bajaj HS](#), Dex T, Groleau M, Stager W, Vinik A; *Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed-ratio combination in North American patients compared with the rest of world*. *BMJ Open Diabetes Research and Care* 2019;7:e000581. doi: 10.1136/bmjdr-2018-000581

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD; Rose JB, Rapattoni W, [Bajaj HS](#); *CANadian CANagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice*. *Diabetes Obes Metab*. 2019 Mar;21(3):691-699

[Bajaj HS](#), Abouhassan T, Ahsan MR, Arnaout A, Hassanein M, Houlden RL, Khan T, Khandwala H, Verma S; *Diabetes Canada Position Statement for People with Types 1 and 2 Diabetes Who Fast During Ramadan*. *Can J Diabetes*. 2019 Feb;43(1):3-12

[Bajaj HS](#), Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R; *SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes*. *Diabetes and Metabolism*. 2018 Dec;44(6):493-499

Opingari E, Partridge ACR, Verma S, [Bajaj HS](#); *SGLT2 inhibitors: practical considerations and recommendations for cardiologists*. *Curr Opin Cardiol*. 2018 Nov;33(6):676-682

[Bajaj HS](#), Al-Jabri B, Verma S; *Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications*. *Curr Opin Cardiol*. 2018 Nov;33(6):665-675

Khan TS, Sharma E, Singh B, Jammu B, Chadha A, Markanday D, Wu YY, [Bajaj HS](#); *Aspirin Increases the Risk of Nondiagnostic Yield of Fine-Needle Aspiration and Biopsy of Thyroid Nodules*. *Eur Thyroid J*. 2018 Jun;7(3):129-132.

[Bajaj HS](#), Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R; *Biomarkers of Vascular Injury after Recent Glucose Intolerance in Pregnancy*; *Diabetes and Vascular Disease Research* 2018 Sep;15(5):449-457

Imran SA, Agarwal G, [Bajaj HS](#), Ross S; *Targets for Glycemic Control*. *Can J Diabetes*. 2018 Apr;42 Suppl 1:S42-S46

Prebtani APH, [Bajaj HS](#), Goldenberg R, Mullan Y; *Reducing the Risk of Developing Diabetes*. *Can J Diabetes*. 2018 Apr;42 Suppl 1:S20-S26

[Bajaj HS](#), Zinman B; *Glucose lowering strategies for cardiac benefits: pathophysiologic mechanisms; Physiology (Bethesda)*. 2018 May 1;33(3):197-210

[Bajaj HS](#), Ye C, Jain E, Venn K, Stein E, Aronson R. *Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study)*. *Diabetes Obes Metab*. 2018 Jan;20(1):195-199]

Bajaj HS, Zinman B, Verma S. *Antihyperglycemic agents and cardiovascular outcomes: recent insights*. *Curr Opin Cardiol*. 2017;32(5):642-650

Aronson R, Goldenberg R, Boras D, Skovgaard R, Bajaj HS. *The Canadian Hypoglycemia Assessment Tool (HAT) Programme: Insights into Rates and Implications of Hypoglycemia from an Observational Study*; *Can J Diabetes*; 2018 Feb;42(1):11-17

Pandey AS, Bajaj HS, Garg V, Pandey A, Verma S. *The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience*. *Curr Opin Cardiol*. 2017 Sep;32(5):633-641

Woo VC, Berard LD, Bajaj HS, Ekoe JM, Senior PA; *Considerations for Initiating an SGLT2 Inhibitor in Individuals with Type 2 Diabetes Using insulin*; *Can J Diabetes*. 2018 Feb;42(1):88-93

Bajaj HS, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R; *Prior Lactation Reduces Future Diabetic Risk through Sustained Post-Weaning Effects on Insulin Sensitivity*. *Am J Physiol Endocrinol Metab*. 2017;312(3): E215-E223

Bajaj HS, Venn K, Ye C, et. al; *Least Glucose Variability and Hypoglycemia is Observed with the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION study)*; *Diabetes Care*. 2017 Feb; 40(2): 194-200

Bajaj HS, Zinman B; *Steno 2 – a small study with a big heart*. *Nature Reviews Endocrinology* 2016 Dec;12(12): 692-694.

Bajaj HS, Zinman B; *Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?* *Can J Diabetes*. October 2016; 40 (5), 379–381

Bajaj HS, Venn K, Ye C, Aronson R; *Long acting insulin glargine titration web tool (LTHome) vs enhanced usual therapy of glargine titration (INNOVATE trial)*; *Diabetes Technol Ther*. 2016 Oct;18(10):610-615

Bajaj HS, Aronson R, Venn K, Ye C, Sharaan ME. *The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-Centered Multidisciplinary Diabetes Program (the NADIR Study)*. *Can J Diabetes*. 2016;40(2):120-5

Bajaj HS, Perera M, Anjana, R, et. al; *Comparison of relative waist circumference between Asian Indian and US adults*; *Journal of Obesity*, 2014;2014:461956

Kashyap SR, Diab D, Baker A, Yerian L, Bajaj HS et al. *Triglyceride Levels and Not Adipokine Concentrations Are Closely Related to Progression of Nonalcoholic Fatty Liver Disease in Obesity Surgery Cohort*; *Obesity* (Silver Spring). 2009 Sep; 17(9):1696-701

Bajaj HS, Brennan DM, Hoogwerf BJ, Doshi KB, Kashyap SR. *Clinical Utility of Waist Circumference in Predicting All-cause Mortality in a Preventive Cardiology Clinic Population: a PreCIS Data Base Study*; *Obesity* (Silver Spring) 2009 Aug; 17(8):1615-20

Bajaj HS, Hilson S. *Obesity and the Risk of New-Onset Atrial Fibrillation*; *Journal of American Medical Association* (JAMA); Apr 2005;293(16): 1974-5

---

#### EXTRAMURAL INVITED ABSTRACTS & PRESENTATIONS

---

Bajaj HS; *Why should we care about NAFLD in type 2 diabetes?* 6<sup>th</sup> annual Diabetes Update; Mont Tremblant; March 2019

Bajaj HS; *The Impact of Diabetes Management on Mood Disorders & ADHD*. Annual Conference Brain & Cognition Discovery Foundation; Toronto; February 2019

Bajaj HS et. al. *Relationship Between Weight Change Patterns and Health Satisfaction in the CANadian Canagliflozin Registry (CanCARE) Study*; Oral presentation; Diabetes Canada annual professional conference in Halifax; October 2018

Woo V, Bajaj HS et. al. *Relationship Between Weight Change Patterns and Health Satisfaction in the CANadian Canagliflozin Registry (CanCARE) Study*; Poster presentation; American Diabetes Association 78<sup>th</sup> annual scientific session in Orlando, US; June 2018

Woo V, Bell A, Clement M, Camacho F, Georgijev N, Rose JB, Rapattoni W and Bajaj HS. *CANadian CANagliflozin REgistry (CanCARE) – A Prospective, Observational, Assessment of Canagliflozin (CANA) Treatment in Type 2 Diabetes Mellitus (T2DM); 12 Month Results*; Poster presentation; American Diabetes Association 78<sup>th</sup> annual scientific session in Orlando, US; June 2018

Brown R, Abitbol A, Bajaj HS et. al. *Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) in PatientS with Type 2 Diabetes—PROGRESS-DIABETES Study*; Poster presentation; American Diabetes Association 78<sup>th</sup> annual scientific session in Orlando, US; June 2018

Bajaj HS. Keynote Lecture: The Impact of Diabetes and its Treatments on Mood and Cognition. Annual Conference Brain & Cognition Discovery Foundation; May 2018

Bajaj HS. *Diabetes Canada 2018 Guidelines.* Clinical Endocrine Rounds, Toronto, ON; April 2018

Bajaj HS. Keynote Lecture: *Basal Insulin & Hypoglycemia and the Role of the Family Physician.* Diabetes Management Update, St. Joseph's Health Centre, Toronto, ON; April 2018

Bajaj HS et. al. *GOAL-RCT: Results from the first randomized trial comparing colesevelam vs. ezetimibe in type 2 diabetes*; Poster presentation; American Heart Association annual scientific session in Anaheim, US; November 2017

Bajaj HS et. al. *DISCOVER: A Prospective Investigation of Disease Management and Clinical Evolution of Second Line Therapies among Patients with T2DM: A First Look at the enrolled cohort in Canada*; Oral Presentation; Diabetes Canada annual professional conference in Edmonton; November 2017

Bajaj HS et. al. *Reduced Health Care Costs With Automated Basal Insulin Titration In Patients With Type 2 Diabetes*; Oral Presentation; Diabetes Canada annual professional conference in Edmonton; November 2017

Woo V, Bajaj HS et. al. *CANadian CANagliflozin REgistry (CanCARE) – A Prospective, Observational, Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus (T2DM); Six Month Results*; Oral Presentation; Diabetes Canada annual professional conference in Edmonton; November 2017

Woo V, Bajaj HS et. al. *Changes in Treatment Patterns at Six Months of the CANadian CANagliflozin REgistry (CanCARE)*; Poster Presentation; Diabetes Canada annual professional conference in Edmonton; November 2017

Bajaj HS et. al. *GOAL-RCT: 3 month results from a randomized trial comparing colesevelam vs. ezetimibe in type 2 diabetes*; Poster Presentation; Diabetes Canada annual professional conference in Edmonton; November 2017

Bajaj HS et. al. *GOAL-RCT: 3 month results from a randomized trial comparing colesevelam vs. ezetimibe in type 2 diabetes*; Highlighted poster presentation; Canadian Cardiovascular Society annual professional conference in Vancouver; October 2017

Bajaj HS et. al. *GOAL-RCT: 3 month results from a randomized trial comparing colesevelam vs. ezetimibe in type 2 diabetes*; Poster presentation; European Association for the Study of Diabetes (EASD) 53<sup>rd</sup> Annual Meeting in Lisbon, Portugal; September 2017

Woo V, Bajaj HS et. al. *Baseline Characteristics and Initial Treatment Patterns of the CANadian CANagliflozin REgistry (CanCARE) – A Prospective, Observational, 12-Month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus (T2DM) in a Usual Clinical Practice in Canada*; Poster presentation; European Association for the Study of Diabetes (EASD) 53<sup>rd</sup> Annual Meeting in Lisbon, Portugal; September 2017

Bajaj HS et. al; GOAL-RCT: 3 month results from a randomized trial comparing colesevelam vs. ezetimibe in type 2 diabetes; Late-breaking Poster presentation; American Diabetes Association 77<sup>th</sup> annual scientific session in San Diego, US; June 2017

Bajaj HS et. al; *Biomarkers of Vascular Injury after Recent Glucose Intolerance in Pregnancy*; Poster presentation; American Diabetes Association 77<sup>th</sup> annual scientific session in San Diego, US; June 2017

Woo V, Bajaj HS et. al; *Baseline Characteristics and Initial Treatment Patterns of the CANadian CANagliflozin REgistry (CanCARE) – A Prospective, Observational, 12-Month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus (T2DM) in a Usual Clinical Practice in Canada*; Poster presentation; American Diabetes Association 77<sup>th</sup> annual scientific session in San Diego, US; June 2017

Seiber J, Bajaj HS et. al; *Reduced health care costs with automated basal insulin titration in patients with type 2 diabetes*; Poster presentation; American Diabetes Association 77<sup>th</sup> annual scientific session in San Diego, US; June 2017

Bajaj HS; *Hot Topics in Cardiology: Complex Cases*. Oral presentation; Canadian Cardiovascular Society, Toronto, ON June 2017

Bajaj HS; *Diabetes Technology, Pump, CBGM, am I going to be cured?* Oral presentation; 6<sup>th</sup> Annual Canadian Endocrine Review Course, London, ON; April 2017

Bajaj HS; Keynote Lecture: *Where does insulin fit in the algorithm for treatment of Type 2 Diabetes in 2017?* 11<sup>th</sup> Annual Practical Issues in Cardiology, Endocrinology and Nephrology, Lakeridge Health, Oshawa, ON; March 2017

Seiber J, Bajaj HS et. al; *Reduced Utilization Of Health Care Provider Resources With Automated Basal Insulin Titration In Patients With Type 2 Diabetes*; E-Poster presentation; 10<sup>th</sup> International Conference on Advanced Technologies & Treatments for Diabetes; February 2017

Mettam S, Bajaj HS et. al; *Modelling the EMPA-REG OUTCOME Study into Long Term Health Outcomes in a Canadian Population*; Oral Presentation; Canadian Diabetes Association (CDA) Professional Conference in Ottawa, Canada; October 2016

Morison D, Bajaj HS et. al; *Endocrine neck ultrasound workshop*; Canadian Society for Endocrinology and Metabolism/ Canadian Diabetes Association (CDA) Professional Conference in Ottawa, Canada; October 2016

Bajaj HS; *Cardiovascular Outcome Trials in Diabetes – a 2016 Update*; Oral presentation; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference at Niagara-on-the-lake, ON; October 2016

Bajaj HS et. al; *Canagliflozin and dapagliflozin, but not liraglutide, reduce Alanine Aminotransferase (ALT) levels in type 2 diabetes: a difference not explained by HbA<sub>1c</sub> or weight change*; Oral Presentation; European Association for the Study of Diabetes (EASD) 52<sup>nd</sup> Annual Meeting in Munich; September 2016

Seiber J, Bajaj HS et. al; *Reduced Utilization Of Health Care Provider Resources With Automated Basal Insulin Titration In Patients With Type 2 Diabetes* Poster presentation; American Diabetes Association 76<sup>th</sup> annual scientific session in New Orleans, LA; June 2016: Kelly Close Top 50 abstracts at ADA

Dailey G, Bailey TS, Bajaj HS et. al; *Insulin Glargine/Lixisenatide Fixed-Ratio Combination Outcomes Are Similar For North American And Rest Of World Type 2 Diabetes Population*: Poster presentation; American Diabetes Association 76<sup>th</sup> annual scientific session in New Orleans, LA; June 2016

Bajaj HS et. al; *Results of the randomized trial of long acting insulin glargine titration web tool (LTHome) vs enhanced usual therapy of glargine titration (INNOVATE trial)*; Poster presentation; 9<sup>th</sup> International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Milan; February 2015

Bajaj HS et. al; *Patient satisfaction score changes in the randomized trial of long acting insulin glargine titration web tool (LTHome) vs enhanced usual therapy of glargine titration (INNOVATE)*; Poster presentation; 9<sup>th</sup> International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Milan; February 2015

Bajaj HS et. al. *Higher rates of progression to dysglycemia among normoglycemic South Asian ethnicity compared to Caucasians in a secondary prevention cohort: a PRACTICE registry study*; Poster presentation; World Diabetes Congress 2015 – International Diabetes Federation, Vancouver; December 2015

Goldenberg R, Bajaj HS et. al. *The Canadian Hypoglycaemia Assessment Tool (HAT) Programme insights into the impact and cost of hypoglycaemia*; Poster presentation; World Diabetes Congress 2015 – International Diabetes Federation, Vancouver; December 2015

Bajaj HS et. al. *Shall We Temporarily Hold Blood-thinning Medications Prior to FNA of Thyroid Nodules?*; Oral presentation; 18<sup>th</sup> Canadian Society of Endocrinology and Metabolism (CSEM) annual conference in Vancouver; December 2015

Sharma E, Bajaj HS et. al. *Shall We Temporarily Hold Blood-thinning Medications Prior to FNA of Thyroid Nodules?*; Oral and poster presentation; 15<sup>th</sup> International Thyroid Congress (ITC) and American Thyroid Association (ATA) annual conference in Orlando, FL; October 2015

Bajaj HS et. al. *Deterioration of glycemic control in South Asians vs. White Caucasians with diabetes and concomitant coronary artery disease – analysis from the PRACTICE Registry*; Poster presentation; European Society of Cardiology Congress 2015 in London, United-Kingdom

Bajaj HS et. al. *Least Glucose Variability and Hypoglycemia is Observed with the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION study)*; Oral presentation; American Diabetes Association 75<sup>th</sup> annual scientific session in Boston, MA; June 2015

Bajaj HS et. al. *Long acting insulin glargine titration web tool (LTHome) vs enhanced usual therapy of glargine titration (INNOVATE trial)*; Poster presentation; American Diabetes Association 75<sup>th</sup> annual scientific session in Boston, MA; June 2015

Gupta M, Bajaj HS; *High rate of progression to dysglycemia in a secondary prevention cohort over five years: findings from the PRACTICE Registry*; Poster presentation; American College of Cardiology (ACC) 64<sup>th</sup> Annual Scientific Sessions in San Diego, CA; March 2015

Miller K, Bajaj HS et. al. *Canagliflozin as Add-on to Antihyperglycemic Regimens in Patients With Type 2 Diabetes*; Poster presentation; American College of Osteopathic Family Physicians (ACOF) 52<sup>nd</sup> Annual Convention & Scientific Seminar in Las Vegas; March 2015

Bajaj HS et. al. *Long acting insulin glargine titration web tool (LTHome) vs enhanced usual therapy of glargine titration (INNOVATE) trial design*; Poster presentation; 8<sup>th</sup> International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris; February 2014

Bajaj HS; *T2D Morning Talk Show - Optimizing Outcomes in Distinct Populations – South Asian Ethnicity*; Oral; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al. *New Insulin Glargine 300 U/ml: Glycemic Control and Hypoglycemia in Insulin Naïve People with T2DM (EDITION 3)*; Oral presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al. *Least Glucose Variability is observed with the Combination of a GLP-1 Agonist and Basal Insulin among Four Commonly-used Insulin Regimen in Type 2 Diabetes (VARIATION study)*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al. *Glycemic Improvement with DPP-4 inhibitor + metformin Fixed-dose combination in patients with Type 2 DM (GIFT study)*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al. *Canadian Endocrinologists are Not Satisfied with Radiology Reporting of Diagnostic Neck ultrasound and US-guided Fine Needle Aspiration of Thyroid Nodules (Survey Report)*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014



Bajaj HS et. al; *Glycemic Control and Hypoglycemia with New Insulin Glargine 300U/mL in People with T1DM (EDITION 4)*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al *Efficacy and Safety of Canagliflozin Across a Range of Treatment Paradigms Used in Patients with Type 2 Diabetes Mellitus*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al; *Insulin vs GLP-1 Receptor Agonist as First Injectable Therapy in Primary Care*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al; *ABC Goal Attainment in Type 2 Diabetes Mellitus Patients in US Primary Care*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Bajaj HS et. al; *Popularity of Sulfonylureas in Real-World Practice: Perspective from Diabetes Forward*; Poster presentation; 17<sup>th</sup> CDA annual conference in Winnipeg, MB; October 2014

Goldenberg R, Cheng A, Bajaj HS et. al; *American Diabetes Association 73<sup>rd</sup> Scientific Section 2014 Update: Perspectives from 3 Canadian Endocrinologists*; Review; Candian Diabetes Association Clinical & Scientific Section (C &SS) Connect Newsletter, Volume 3 Issue 2, September 2014

Bajaj HS et. al; *Least Glucose Variability is observed with the Combination of a GLP-1 Agonist and Basal Insulin among Four Commonly-used Insulin Regimen in Type 2 Diabetes (VARIATION study)*; Poster presentation; European Association for the Study of Diabetes (EASD) 50<sup>th</sup> annual meeting in Vienna, Austria; September 2014

Bajaj HS et. al; *Glycemic Improvement with DPP-4 inhibitor + metformin Fixed-dose combination in patients with Type 2 DM (GIFT study)*; publication at American Diabetes Association 74<sup>th</sup> annual scientific session in San Francisco, CA; June 2014

Bajaj HS; *Medication Non-Adherence in Chronic Disease: The GIFT of Getting More with Less*; Oral presentation; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference at Deerhurst, ON; October 2014

Bajaj HS et. al; *Insulin Workshop: Administration, Initiation to Intensification*; Oral presentation; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference at Deerhurst, ON; October 2012

Bajaj HS; Scientific update; *DPP-4 Inhibitors and Cardiovascular Events: Implications of the SAVOR and EXAMINE Trials*; Review; Candian Diabetes Association Clinical & Scientific Section (C &SS) Connect Newsletter, Volume 2 Issue 2, January 2014

Bajaj HS; *Latest Advances in Individualizing Treatment for Patients with Diabetes: "SGLT-2 Inhibitors: A Novel Class of Agents and Its Role in Type 2 Diabetes"*; Oral presentation at Primary care update in Ottawa, ON; November 2013

Bajaj HS et. al; *Endocrinologist performed ultrasound-guided fine needle aspiration of thyroid nodules in Toronto*; oral presentation; Oral presentation; 16<sup>th</sup> CDA annual conference in Montreal, QC; October 2013

Bajaj HS et. al; *Once-daily Lixisenatide in Combination With Basal Insulin ± Oral Antihyperglycemic Agents in Patients With Type 2 Diabetes Selectively Reduces Postprandial Hyperglycemic Daytime Exposure*; poster presentation; 16<sup>th</sup> CDA annual conference in Montreal, QC; October 2013

Bajaj HS et. al; *Therapeutic Efficacy of Lixisenatide Added to Basal Insulin is Greater When FPG is Well Controlled*; poster presentation; 16<sup>th</sup> CDA annual conference in Montreal, QC; October 2013

Bajaj HS (presenter); *Empagliflozin as Add-On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)*; poster presentation; 16<sup>th</sup> CDA annual conference in Montreal, QC; October 2013

Bajaj HS (presenter); *Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension*; poster presentation; 16<sup>th</sup> CDA and Vascular annual conference in Montreal, QC; October 2013

Bajaj HS; *Thyroid ultrasound and fine needle aspiration workshop for endocrinologists*; Endocrinology division rounds, McMaster university; October 2013

Bajaj HS; *Common pitfalls of thyroid disease management in primary care*; oral presentation; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference at Niagara on the lake, ON; October 2013

Bajaj HS et. al; *Endocrinologist performed ultrasound-guided fine needle aspiration of thyroid nodules in Toronto*; oral presentation; 2<sup>nd</sup> World Congress on Thyroid Cancer in Toronto, ON; July 2013

Bajaj HS et. al; *The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-centered Multi-disciplinary Diabetes Program (NADIR study)*; Poster presentation; 22<sup>nd</sup> AACE annual conference in Phoenix, AZ; May 2013

Bajaj HS et. al; *The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-centered Multi-disciplinary Diabetes Program (NADIR study)*; Poster presentation; 15<sup>th</sup> CDA annual conference in Vancouver, BC; October 2012

Bajaj HS; *Clinical Focus: Type 2 DM management and the role of incretin therapy*; Review, The Medical Post – October 9, 2012

Bajaj HS; *Update in PCOS; Osteoporosis workshop*; oral presentations; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference at Deerhurst, ON; October 2012

Bajaj HS; *Early and Aggressive treatment of Type 2 Diabetes*; eNewsletter development for mdBriefCase Inc. and the Canadian Society of Endocrinology and Metabolism (CSEM), published July 2012

Bajaj HS; *Insulin and injection barriers*; eNewsletter development for mdBriefCase Inc. and the Canadian Society of Endocrinology and Metabolism (CSEM), published March 2012

Bajaj HS; *What is new in Diabetes Mellitus?* Oral presentation; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference in Niagara Falls, ON, October 2011

Bajaj HS; *Postmenopausal Osteoporosis – the silent thief!* Oral presentation - Medicine noon conference, William Osler Health System in Brampton, ON; September 2011

Bajaj HS; *Bridging the Gap of Diabetes management in South Asian population*; oral presentation; Canadian Association of Physicians of Indian Heritage annual conference in Toronto, ON; September 2011

Bajaj HS; *Impaired fasting glucose or Impaired Glucose Tolerance: Shall we Treat?* Review; LMC Clinical Practice Update: August 10, 2011

Bajaj HS; *Clinical Focus: Diabetes in the South Asian Community*; Review; The Medical Post - July 12, 2011

Bajaj HS; *Management of thyroid nodules in pregnancy – use of ultrasound technology by Endocrinologists*; Oral presentation; Toronto-wide Clinical Endocrine Rounds; March 2011

Bajaj HS; *Incretin therapy for treatment of type 2 Diabetes. Gastroparesis – clinical features and management*; oral presentation; Canadian Diabetes Association Toronto West Chapter; March 2011

Bajaj HS; *Is treating type 2 Diabetes just about glycemic control?* Oral presentation; Manitoba Association of Asian Physician's Winter Symposium; February 2011

Bajaj HS; *Evidence-based Goals of Diabetes Management*; oral presentation; North Indian Medical and Dental Association of Canada (NIMDAC) annual conference in Niagara on the lake; October 2010

Bajaj HS; *Endocrinology Update 2010*; oral presentation - Medicine noon conference - Humber River Regional Hospital in Toronto, ON; May 2010

Bajaj HS; *Insulin Therapy in the In-Hospital Setting: Rationale & Process*; oral presentation - Hospitalist rounds at William Osler Health System in Brampton, ON; November 2009

Cheng V, Bajaj HS et al. *Thyroid Related Adverse Effects Of Glatiramer Are Equivalent To Interferon B Treatment For Multiple Sclerosis*; Poster presentation at Endocrine Society 92<sup>th</sup> Annual Meeting 2010 in San Diego, CA; June 2010

Bajaj HS, Kashyap SR, et al. *Clinical Utility of Waist Circumference in a Preventive Cardiology Clinic Population*; Oral and poster presentations at Annual Symposium of Dietrich Diabetes Research Institute, Cleveland, OH; November 2008

Bajaj HS; *Should every patient with Type 2 DM be on a statin?* Oral presentation - Internal Medicine Noon conference at Fairview Hospital in Cleveland, OH; October 2008

Bajaj HS, *Pheochromocytoma*; Oral presentation at American Association of Clinical Endocrinologist 10<sup>th</sup> Annual Symposium of Ohio River Regional Chapter in Cincinnati, OH; August 2008

Diab D, Bajaj HS, et al.; *Insulin resistance predicts Non-alcoholic Fatty Liver Disease in a bariatric population*; Poster presentation at Endocrine Society 90<sup>th</sup> Annual Meeting 2008 in San Francisco, CA; June 2008

Bajaj HS, Kashyap SR, et al.; *Waist circumference and not BMI predicts All-cause mortality and DM*; Poster presentation at American Diabetic Association (ADA) 68<sup>th</sup> Annual Scientific Sessions 2008 in San Francisco, CA; June 2008

Bajaj HS, Zimmerman R.; *Interferon- $\beta$  Induced Graves' disease in a Patient with Multiple Sclerosis*; Poster presentation at American Association of Clinical Endocrinologists (AACE) 17<sup>th</sup> Annual Meeting 2008 in Orlando, FL; May 2008

Bajaj HS, Pereira MA, *Asian Indians: large, but not obese*; Oral and poster presentations at American College of Physicians (ACP), Minnesota chapter annual session 2005 in Minneapolis, MN; November 2005

Bajaj HS, Stuart D, *Persistently Metastatic Thyroid Cancer With Undetectable Thyroglobulin (Tg): Can Decisions Be Based On Tg Alone?*; Poster presentation at American College of Physicians (ACP), Minnesota chapter annual session 2004 in Minneapolis, MN; November 2004